Protobios is an SME located in Tallinn, Estonia, that develops high-tech clinical tools, and provides R&D services for the biomedical community. Protobios has developed Mimotope Variation Analysis (MVA), a method that allows to generate profiles of antibody immune response (immune profiles) from peripheral blood. MVA data on different severe diseases including chronic neurological conditions suggest that individual immune profiles correspond to exposure of specific foreign antigens (commensal and pathogenic microbiome) and self-antigens.
In OPADE, Protobios will perform immune epitope profiling by MVA of samples from patients with Major Depressive Disorder (MDD) which will be provided by the clinical partners of the project (UNISA – Italy, FUS – Columbia, ACC – The Netherlands, IDIBGI – Spain, MED – Turkey). The obtained data will contribute to the establishment of patient profiles to predict and optimise the efficacy of the antidepressants prescribed.
This personalized approach to treatment improves outcomes for MDD patients and reduces the trial-and-error process of finding the most effective medication. Overall, the integrated patient profiles generated by OPADE will contribute to a better understanding of MDD and aid in the development of improved diagnostics and therapies for the disorder.